News

TiGenix to present at the Crohn’s and Colitis Foundation’s Novel Technologies in Inflammatory Bowel Disease workshop in New York

Leuven (BELGIUM) – May 10, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, will present at the Crohn’s and Colitis Foundation’s Novel Technologies in Inflammatory Bowel Disease (IBD) Workshop, taking place on May 15-16, 2017 at the Doubletree by Hilton Metropolitan New York Hotel.

2017-06-21T10:04:43+00:00